Key Stats for Roivant Sciences Stock
- Price change for Roivant Sciences stock in the last 6 months: 40%
- $ROIV Stock Price as of Sep. 8: $41
- 52-Week High: $43
- $ROIV Stock Price Target: $42
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Roivant Sciences (ROIV) stock jumped 22% in premarket trading after some genuinely exciting drug trial news. By the end of the day, the stock was up 19%.
The company’s Pulmovant subsidiary shared topline results from a Phase 2 study called PHocus, which tested a drug called mosliciguat in patients with a serious lung condition called PH-ILD.
That stands for pulmonary hypertension associated with interstitial lung disease, a progressive condition where blood pressure in the lungs rises because of underlying lung disease. A professor from Université Paris-Saclay presented the results at a major European medical conference.
Mosliciguat itself is an inhaled drug designed to activate a specific enzyme pathway, and it’s being tested as a potential treatment option for PH-ILD patients who currently don’t have many good choices.
Alongside the Phase 2 news, Roivant announced it has already started a Phase 3 study called PHrontier for the same drug, and it is now enrolling patients.
Moving straight into a Phase 3 trial signals real confidence in the earlier data, even though the announcement didn’t include specific efficacy and safety numbers.
Roivant also held an investor call the same morning to walk through the findings in more depth.
This isn’t the only recent win for Roivant Sciences stock.
Just weeks earlier, in late August, the company’s Priovant subsidiary got FDA approval for a drug called LISRAYA, also known as brepocitinib, to treat dermatomyositis, a serious inflammatory disease.
Roivant operates through a handful of subsidiaries, each focused on different areas like pulmonary and autoimmune diseases, so two positive pieces of news landing close together adds real momentum to the stock.
See analysts’ growth forecasts and price targets for Roivant Sciences stock (It’s free) >>>
What the Market Is Telling Us About Roivant Sciences Stock
Today’s move pushed Roivant Sciences stock above its previous 52-week high, suggesting investors see this as more than a routine trial update.
The broader market wasn’t doing much today. The Nasdaq was roughly flat, while the S&P 500 and Dow Jones were both slightly lower.
That makes it clear this rally is about Roivant specifically, not some broader market trend lifting biotech stocks generally.
Mosliciguat is still an investigational drug, meaning it hasn’t been approved yet, and it will need to clear the ongoing Phase 3 trial along with regulatory review before it could reach patients.
Still, moving from Phase 2 data straight into Phase 3 enrollment shows Roivant is treating this as a priority program.
Combined with the recent LISRAYA approval, Roivant Sciences stock is benefiting from a pipeline that’s actually delivering results right now, not just promising something years down the road.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Roivant Sciences Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
